RecruitingNot ApplicableNCT07545473

Retinal Hyperspectral Imaging in Neurodegenerative Diseases

Sponsor

Center for Eye Research Australia

Enrollment

930 participants

Start Date

Oct 11, 2021

Study Type

INTERVENTIONAL

Conditions

Dementia Alzheimer Disease Parkinson Disease Lewy Body Disease Frontotemporal Dementia Vascular Dementia Neurodegenerative Diseases Niemann-Pick Diseases

Summary

Hyperspectral retinal imaging is a non-invasive imaging modality in which a series of images of the retina are captured using light of different wavelengths. The resulting "hypercube" of data provides a wealth of information about the retinal structure. Our group has developed evidence supporting a role for this technology in the detection of retinal amyloid beta in Alzheimer's disease. We are undertaking further studies to establish the role of this method in the assessment of people with dementia, or those at risk of Alzheimer's disease. In addition, we wish to test whether the approach may have value in other forms of dementia or neurodegenerative disease such as Parkinson's disease, Lewy-Body dementia or vascular dementia.

Eligibility

Min Age: 30 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Hyperspectral camera for people with alzheimer disease, dementia, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 30 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEHyperspectral camera

Hyperspectral imaging is performed with the Metabolic Hyperspectral Retinal Camera (Optina Diagnostic, Montreal, Canada) and a prototype camera developed by researchers at the Centre for Eye Research Australia (CERA). The Metabolic Hyperspectral Retinal Camera is similar to a typical fundus imager but it incorporates a tunable light source which is able to transmit safe light levels within a wavelength range covering the visible to near infrared with a narrow bandwidth (\< 3nm). This instrument is capable of imaging a 26° field-of-view of retina at 90 wavelengths in less than a second, thus minimizing discomfort and limiting the influence of eye movements. The hyperspectral camera developed by CERA researchers is a non-mydriatic fundus camera that uses light emitting diodes (LEDs) and an optical variable bandpass filter to tune the illumination wavelengths.